Leber's disease with G3635A mutation

Article

In this article, the authors report on a case of two brothers with genetically proved Leber's disease associated with the rarer mutation G3635A, which is the only family case encountered in Bulgaria thus far.

The prevalence of Leber's disease is estimated at around 1/15000–1/50000 people. The clinical manifestation is acute or subacute, painless loss of central vision, which is usually persistant (with varying chance for recovery of vision depending on the mutation).

The most frequently found mutations in European patients are in the 3460, 11778 and 14484 nucleotides (associated with 90% of the cases). However, there are some other primary mutations, as well as secondary mutations that mostly affect the penetrance of the disease, which is incomplete in the LHON families - only 50% of men and 10% of women with the typical mtDNA mutations develop optic neuropathy.1–4

OCT: Valuable assessment

Some studies in LOHN have found that the fibres in the nasal quadrant show the lowest reduction, while the first and the most severely affected ones are the temporal segments, and that RNFL is thickened during the early stages of the optic neuropathy (duration of less than 6 months), while it shows thinning in the later, atrophic stages (more than 6 months).7

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.